Preview

Современная ревматология

Расширенный поиск

Респираторные нарушения при полимиозите/дерматомиозите

https://doi.org/10.14412/1996-7012-2014-1-31-38

Полный текст:

Аннотация

Идиопатические воспалительные миопатии (ИВМ) – редкие аутоиммунные заболевания, характеризующиеся воспалительным поражением скелетной мускулатуры. К наиболее распространенным ИВМ относят: полимиозит (ПМ), дерматомиозит (ДM), которые характеризуются клинико-иммунологической неоднородностью и различным ответом на лечение. Наиболее часто встречающимся системным проявлением при ПМ/ДМ является поражение дыхательной системы. Развивающиеся при этом респираторные нарушения весьма разнообразны и могут опережать симптомы мышечной патологии.

Об авторах

Ольга Алексеевна Антелава
Кафедра ревматологии ФППОВ; 119048, Москва, Трубецкая ул., 8, стр. 2
Россия


И. Б. Бондаренко
кафедра терапии и профболезней ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, Москва, Россия; 119048, Москва, Трубецкая ул., 8, стр. 2
Россия


Наталья Владимировна Чичасова
Кафедра ревматологии ФППОВ; 119048, Москва, Трубецкая ул., 8, стр. 2
Россия


E L Насонов
Кафедра ревматологии ФППОВ; 119048, Москва, Трубецкая ул., 8, стр. 2; ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия; 115522, Москва, Каширское ш., 34А
Россия


Литература

1. <div><p>Kalluri M, Oddis CV. Pulmonary Manifestations of the Idiopathic Inflammatory Myopathies. Clin Chest Med. 2010;31:501–12. DOI: http://dx.doi.org/10.1016/j.ccm.2010.05.008.</p><p>Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7. DOI: http://dx.doi.org/10.1056/NEJM197502202920807.</p><p>Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–82. DOI: http://dx.doi.org/10.1016/S0140-6736(03)14368-1.</p><p>Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70(6):360–74.</p><p>Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology. 2003;61(3):288–9. DOI: http://dx.doi.org/10.1212/WNL.61.3.288.</p><p>Benbassat J, Geffel D, Zlotnick A. Epidemiology of polymyositis-dermatomyositis in Israel, 1960–76. Isr J Med Sci. 1980;16(3):197–200.</p><p>Koh ET, Seow A, Ong B, et al. Adult onset polymyositis/ dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993;52(12):857–61. DOI: http://dx.doi.org/10.1136/ard.52.12.857.</p><p>Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol. 1990;17(10):1329–34.</p><p>Kaipiainen-Seppanen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. J Intern Med. 1996;240(2):81–4. DOI: http://dx.doi.org/10.1046/j.1365-2796.1996.14843000.x.</p><p>Weitoft T. Occurrence of polymyositis in the county of Gavleborg, Sweden. Scand J Rheumatol. 1997;26(2):104–6. DOI: http://dx.doi.org/10.3109/03009749709115827.</p><p>Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006;8(1):R13. DOI: http://dx.doi.org/10.1186/ar1862.</p><p>O’Hanlon TP, Carrick DM, Arnett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. Medicine (Baltimore). 2005;84(6):338–49. DOI: http://dx.doi.org/10.1097/01.md.0000189818.63141.8c.</p><p>O’Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006;85(2):111–27. DOI: http://dx.doi.org/10.1097/01.md.0000217525.82287.eb.</p><p>Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):859–90, viii.</p><p>O’Leary P.A., Waisman M. Dermatomyositis: A stady of forty cases. Arch Dermatol Syph. 1940;41:1001–19. DOI: http://dx.doi.org/10.1001/arch-derm.1940.01490120003001.</p><p>Torres C, Belmonte R, Carmona L, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity. 2006;39(3):205–15. DOI: http://dx.doi.org/10.1080/08916930600622603.</p><p>Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2005;7(2):99–105. DOI: http://dx.doi.org/10.1007/s11926-005-0061-4.</p><p>Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26(1):459–67. DOI: http://dx.doi.org/10.1016/S0049-0172(96)80026-6.</p><p>Schwarz MI, Sutarik JM, Nick JA, et al. Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis. Am J Respir Crit Care Med. 1995;151(6):2037–40. DOI: http://dx.doi.org/10.1164/ajrc-cm.151.6.7767555.</p><p>Korkmaz C, Ozkan R, Akay M, et al. Pneumomediastinum and subcutaneous emphysema associated with dermatomyositis. Rheumatology (Oxford). 2001;40(4):476–8. DOI: http://dx.doi.org/10.1093/rheumatol-ogy/40.4.476.</p><p>Goff BL, Cherin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum. 2009;61(1):108–18. DOI: http://dx.doi.org/10.1002/art.24372.</p><p>Sano M, Suzuki M, Sato M, et al. Fatal respiratory failure due to polymyositis. Intern Med. 1994;33(3):185–7. DOI: http://dx.doi.org/10.2169/internalmedi-cine.33.185.</p><p>Selva-O’Callaghan A, Sanchez-Sitjes L, Munoz-Gall X, et al. Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation. Rheumatology (Oxford). 2000;39(8):914–6. DOI: http://dx.doi.org/10.1093/rheumatol-ogy/39.8.914.</p><p>Martin L, Chalmers IM, Dhingra S, et al. Measurements of maximum respiratory pressures in polymyositis and dermatomyositis. J Rheumatol. 1985;12(1):104–7.</p><p>Braun NM, Arora NS, Rochester DF. Respiratorymuscle and pulmonary function in polymyositis and other proximal myopathies. Thorax. 1983;38(8):616–23. DOI: http://dx.doi.org/10.1136/thx.38.8.616.</p><p>Teixeira A, Cherin P, Demoule A, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord. 2005;15(1):32–9. DOI: http://dx.doi.org/10.1016/j.nmd.2004.09.006.</p><p>Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford). 2006;45 Suppl 4:iv18–21. DOI: http://dx.doi.org/10.1093/rheumatology/kel311.</p><p>Stern R, Godbold JH, Chess Q, et al. ECG abnormalities in polymyositis. Arch Intern Med. 1984;144(11):2185–9. DOI: http://dx.doi.org/10.1001/arch-inte.1984.04400020097015.</p><p>Marie I, Hachulla E, Cherin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005;53(2):155–65. DOI: http://dx.doi.org/10.1002/art.21083.</p><p>Hepper NG, Ferguson RH, Howard FM Jr. Three types of pulmonary involvement in polymyositis. Med Clin North Am. 1964;48:1031–42.</p><p>Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2005;17(6):701–6. DOI: http://dx.doi.org/10.1097/01.bor.0000179949.65895.53.</p><p>Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614–22. DOI: http://dx.doi.org/10.1002/art.10794.</p><p>Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibodypositive interstitial lung disease. Arthritis Rheum. 2009;60(7):2183–92. DOI: http://dx.doi.org/10.1002/art.24631.</p><p>Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newlydiagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297–301. DOI: http://dx.doi.org/10.1136/ard.2003.006122.</p><p>Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32(1):57–64.</p><p>Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28(6):639–46. DOI: http://dx.doi.org/10.1007/s10067-009-1110-6.</p><p>Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44(10):1282–6. DOI: http://dx.doi.org/10.1093/rheumatology/keh723.</p><p>Vancsa A, Csipo I, Nemeth J, et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29(9):989–94. DOI: http://dx.doi.org/10.1007/s00296-009-0884-9.</p><p>La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39(3):249–53. DOI: http://dx.doi.org/10.1080/08916930600623791.</p><p>Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182–5. DOI: http://dx.doi.org/10.1164/ajrc-cm.164.7.2103110.</p><p>Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44(6):585–96. DOI: http://dx.doi.org/10.1111/j.1365-2559.2004.01896.x.</p><p>Beasley MB, Franks TJ, Galvin JR, et al. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med. 2002;126(9):1064–70.</p><p>Minai OA. Pulmonary hypertension in polymyositis/dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy. Lupus. 2009;18(11):1006–10. DOI: http://dx.doi.org/10.1177/0961203309102822.</p><p>Yaqub S, Moder KG, Lacy MQ. Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc. 2004;79(5):687–9. DOI: http://dx.doi.org/10.4065/79.5.687.</p><p>Denbow CE, Lie JT, Tancredi RG, et al. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum. 1979;22(10):1088–92. DOI: http://dx.doi.org/10.1002/art.1780221007.</p><p>Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1851–6. DOI: http://dx.doi.org/10.1164/ajrc-cm.154.6.8970380.</p><p>Cannon GW, Ward JR, Clegg DO, et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum. 1983;26(10):1269–74. DOI: http://dx.doi.org/10.1002/art.1780261015.</p><p>Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol. 2004;49(3):235–44. DOI: http://dx.doi.org/10.1016/S0720-048X(03)00094-9.</p><p>Marder W, Mc Cune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med. 2007;28(4):398–417. DOI: http://dx.doi.org/10.1055/s-2007-985612.</p><p>Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest. 2003;123(4):1096–103. DOI: http://dx.doi.org/10.1378/chest.123.4.1096.</p><p>Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53–9. DOI: http://dx.doi.org/10.1136/thx.2006.069237.</p><p>Kurasawa K, Nawata Y, Takabayashi K, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol. 2002;129(3):541–8. DOI: http://dx.doi.org/10.1046/j.1365-2249.2002.01933.x.</p><p>Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47(9):738–42. DOI: http://dx.doi.org/10.1136/thx.47.9.738.</p><p>Passadore I, Iadarola P, Di Poto C, et al. 2-DE and LC-MS/MS for a comparative proteomic analysis ofBALf from subjects with different subsets of inflammatory myopathies. J Proteome Res. 2009;8(5):2331–40. DOI: http://dx.doi.org/10.1021/pr800943t.</p><p>Targoff IN, Trieu EP, Plotz PH. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992 Jul;35(7):821–30. DOI: http://dx.doi.org/10.1002/art.1780350718.</p><p>Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47(9):738–42. DOI: http://dx.doi.org/10.1136/thx.47.9.738.</p><p>Levine SM, Raben N, Xie D, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum. 2007;56(8):2729–39. DOI: http://dx.doi.org/10.1002/art.22790.</p><p>Englund P, Wahlstrom J, Fathi M, et al. Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 2007;56(1):372–83. DOI: http://dx.doi.org/10.1002/art.22293.</p><p>D’Cruz D, Keser G, Khamashta MA, et al. Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. J Rheumatol. 2000;27(1):161–4.</p><p>Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis. 2000;59 (4):257–62. DOI: http://dx.doi.org/10.1136/ard.59.4.257.</p><p>Fujita J, Dobashi N, Tokuda M, et al. Elevation of cytokeratin 19 fragment in patients with interstitial neumonia associated with polymyositis/dermatomyositis. J Rheumatol. 1999;26(11):2377–82.</p><p>Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012 May;51(5):800–4. DOI: 10.1093/rheumatology/ker408. Epub 2011 Dec 30.</p><p>Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013 Aug;65(8):1307–15. DOI: 10.1002/acr.21992.</p><p>Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature. Chest. 2009;135(6):1550–6. DOI: http://dx.doi.org/10.1378/chest.08-2233.</p><p>Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012 Jul;91(4):206–11. DOI: 10.1097/MD.0b013e318260977c.</p><p>Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34(5):1012–8.</p><p>Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999;26(7):1527–33.</p><p>Maccioni FJ, Colebatch HJ. Management of fibrosing alveolitis with polymyositis dermatomyositis. Aust N Z J Med. 1990;20(6):806–10. DOI: http://dx.doi.org/10.1111/j.1445-5994.1990.tb00428.x.</p><p>Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol. 1989;16(12):1592–6.</p><p>Yoshida T, Koga H, Saitoh F, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med. 1999;38(9):733–8. DOI: http://dx.doi.org/10.2169/internalmedicine.38.733.</p><p>Marie I, Hatron PY, Hachulla E, et al. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998;25(7):1336–43.</p><p>Rowen AJ, Reichel J. Dermatomyositis with lung involvement, successfully treated with azathioprine. Respiration. 1983;44(2):143–6. DOI: http://dx.doi.org/10.1159/000194540.</p><p>Gruhn WB, Diaz-Buxo JA. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol. 1987;14(5):1045–7.</p><p>Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201–6. DOI: http://dx.doi.org/10.1007/s00408-009-9146-6.</p><p>Bongartz T, Ryu JH, Matteson EL. Is tacrolimus effective for treating antisynthetase-associated interstitial lung disease? Nat Clin Pract Rheumatol. 2005;1(2):80–1. DOI: http://dx.doi.org/10.1038/ncprheum0067.</p><p>Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8): 2439–46. DOI: http://dx.doi.org/10.1002/art.21240.</p><p>Roos N, Poulalhon N, Farge D, et al. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther, 2007;321(2):583–9. DOI: http://dx.doi.org/10.1124/jpet.106.117051.</p><p>Hervier B, Masseau A, Mussini JM, et al. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine. 2009;76(5):575–6. DOI: http://dx.doi.org/10.1016/j.jbspin.2009.02.004.</p><p>Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. A Randomized, PlaceboPhase Trial. Arthritis Rheum. 2013;65(2):314–24. DOI: http://dx.doi.org/10.1002/art.37754.</p><p>Tazelaar HD, Viggiano RW, Pickersgill J, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990;141(3):727–33. DOI: http://dx.doi.org/10.1164/ajrccm/141.3.727.</p></div><br />


Для цитирования:


Антелава О.А., Бондаренко И.Б., Чичасова Н.В., Насонов E.L. Респираторные нарушения при полимиозите/дерматомиозите. Современная ревматология. 2014;8(1):31-38. https://doi.org/10.14412/1996-7012-2014-1-31-38

For citation:


Antelava O.A., Bondarenko I.B., Chichasova N.V., Насонов E.L. Respiratory disorders in patients with polymyositis/dermatomyositis. Modern Rheumatology Journal. 2014;8(1):31-38. (In Russ.) https://doi.org/10.14412/1996-7012-2014-1-31-38

Просмотров: 804


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)